Citations

Clear

3942 citation(s) found for "To, Van".

Still under the microscope: Can a surgical aptitude test predict otolaryngology resident performance?
Moore, Eric J. , Abel, Kathryn M. Van , Carlson, Matthew L. , Price, Daniel L. , Van Abel, Kathryn M

Mayo Clinic

The Laryngoscope | June 19, 2014 | Volume: 125 | Issue: 2 | Pages: No page available

10.1002/lary.24791 | PMID 24945869 Get It

Objectives/HypothesisApplication to otolaryngology–head and neck surgery residency is highly competitive, and the interview process strives to select qualified applicants with a high aptitude for the specialty. Commonly employed criteria for applicant selection have failed to show correlation with proficiency during residency training. We evaluate the correlation between the results of a surgical aptitude test administered to otolaryngology resident applicants and their performance during residency.Study DesignRetrospective study at an academic otolaryngology–head and neck surgery residency program.MethodsBetween 2007 and 2013, 224 resident applicants participated in a previously described surgical aptitude test administered at a microvascular surgical station. The composite score and attitudinal scores for 24 consecutive residents who matched at our institution were recorded, and their residency performance was analyzed by faculty survey on a five‐point scale. The composite and attitudinal scores were analyzed for correlation with residency performance score by regression analysis.ResultsTwenty‐four residents were evaluated for overall quality as a clinician by eight faculty members who were blinded to the results of surgical aptitude testing. The results of these surveys showed good inter‐rater reliability. Both the overall aptitude test scores and the subset attitudinal score showed reliability in predicting performance during residency training.ConclusionsThe goal of the residency selection process is to evaluate the candidate's potential for success in residency and beyond. The results of this study suggest that a simple‐to‐administer clinical skills test may have predictive value for success in residency and clinician quality.Level of Evidence4 Laryngoscope, 125:E57–E61, 2015
scikit-image: image processing in Python
Schönberger, Johannes L., Nunez-Iglesias, Juan , Boulogne, François , Warner, Joshua , Yager, Neil , Gouillart, Emmanuelle , Warner, Joshua D, Walt, Stéfan van der , Yu, Tony

Mayo Clinic

PeerJ | June 19, 2014 | Volume: 2 | Issue: No issue available | Pages: e453

10.7717/peerj.453 | PMID 25024921 Get It

Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology
Bai, Julio C. , Biagi, Federico , Card, Tim , Ciacci, Carolina , Ciclitira, Paul J. , Green, Peter H.R. , Hadjivassiliou, Marios , Holdoway, Anne , Heel, David A. van , Kaukinen, Katri , Leffler, Daniel A. , Leonard, Jonathan N., McGough, Norma, Davidson, Mike, Swift, G L, Walker, Marjorie M. , Zingone, Fabiana , Sanders, David S. , Group, Authors of the BSG Coeliac Disease Guidelines Development, Ludvigsson, Jonas F. , Lundin, Knut E. A. , Murray, Joseph A. , Group, Authors of the BSG Coeliac Disease Guidelines Development, van Heel, David A , Ciacci, Carolina

Mayo Clinic

Gut | June 11, 2014 | Volume: 63 | Issue: 8 | Pages: 1210-1228

10.1136/gutjnl-2013-306578 | PMID 24917550 Get It

A multidisciplinary panel of 18 physicians and 3 non-physicians from eight countries (Sweden, UK, Argentina, Australia, Italy, Finland, Norway and the USA) reviewed the literature on diagnosis and management of adult coeliac disease (CD). This paper presents the recommendations of the British Society of Gastroenterology. Areas of controversies were explored through phone meetings and web surveys. Nine working groups examined the following areas of CD diagnosis and management: classification of CD; genetics and immunology; diagnostics; serology and endoscopy; follow-up; gluten-free diet; refractory CD and malignancies; quality of life; novel treatments; patient support; and screening for CD.
Use and Out-of-Pocket Costs of Insulin for Type 2 Diabetes Mellitus From 2000 Through 2010
Ross, Joseph S. , Houten, Holly K. Van , Beran, David , Yudkin, John , Shah, Nilay D. , Van Houten, Holly K, Lipska, Kasia J. , Ross, Joseph S

Mayo Clinic

JAMA | June 10, 2014 | Volume: 311 | Issue: 22 | Pages: 2331

10.1001/jama.2014.6316 | PMID 24915266 Get It

OC-030 Effective Stratification Of Hepatocellular Carcinoma Risk In Primary Biliary Cirrhosis: Results Of A Multi-centre International Study
Trivedi, PJ, Buuren, H. van, Battezzati, Pm, Floreani, Annarosa , Ponsioen, Cyriel Y. , Poupon, R., Mayo, Marlyn J. , Talwalkar, Jayant A., Burroughs, AK, Nevens, Frederik , Bruns, Tony , Li, KK, Cheung, Angela , Cazagon, N, Franceschet, I., Imam, Mohamad , Pieri, Giulia , Kanwar, Pushpjeet, Lindor, Keith D. , Lammers, Willem J. , Janssen, Harry L.A. , Invernizzi, Pietro , Parés, Albert , Corpechot, Christophe , Mason, Andrew L. , Kowdley, Kris V. , Kumagi, Teru , Lleò, Ana , Caballería, Llorenç , Boonstra, Kirsten , Vries, Esther de , Hansen, Bettina E. , Hirschfield, Gideon M. , Bruns, Tony

Mayo Clinic

Gut | June 9, 2014 | Volume: 63 | Issue: Suppl 1 | Pages: A15-A16

10.1136/gutjnl-2014-307263.30 Get It

Introduction Hepatocellular carcinoma (HCC) is an important but infrequent outcome in primary biliary cirrhosis (PBC). Improved risk evaluation is an important goal for stratified surveillance. Methods Risk-factor analysis of the ‘Global PBC Study Group’ comprising 15 centres across North America and Europe spanning >40-years follow-up was performed using Cox proportional hazards model, logistic regression and Kaplan-Meier estimates (SPSSv21). Results Of 3546 patients with PBC (med. follow-up 8.6 yrs; IQR 4.4–14.1), 131 developed HCC. Excluding those who developed HCC within 12 months of PBC diagnosis (n = 23), median time to HCC was 12.7 yrs (6.9–16.8) and subsequent survival 1.1 yrs. (0.2–2.7). At diagnosis, factors associated with HCC development were male gender (adj. HR: 4.4;1.4–12.2, p = 0.014) and thrombocytopenia (adj. HR: 4.5;1.4–14.8, p = 0.012). Use of ursodeoxycholic acid per-se was not associated with future risk of HCC, but stratification of risk by biochemical response at 12 months was effective by Rotterdam (adj. HR: 8.9;2.1–37.3, P = 0.003), Paris-I (adj. HR: 7.6;2.0–29.0, p = 0.003) or Toronto criteria (HR: 5.6;1.6–18.8, P = 0.006). Five (4.6 vs. 0.2%) and 10-year (13%vs.1.9%) HCC incidence was significantly increased for biochemical non-responders (p = 2.2 × 10 –9 ), and by multivariate analysis non-response remained the only significant risk factor. Conclusion Our uniquely powered cohort allows robust demonstration that 12-month biochemical non-response is associated with an increased risk of developing HCC in PBC. Routine surveillance in those achieving biochemical response is unlikely cost-effective. Disclosure of Interest None Declared.
Histone Deacetylase Inhibition Destabilizes the Multi‐Potent State of Uncommitted Adipose‐Derived Mesenchymal Stromal Cells
Dudakovic, Amel , Camilleri, Emily T. , Lewallen, Eric A. , McGee‐Lawrence, Meghan E. , Riester, Scott M. , Montecino, Martı́n , Stein, Gary S., Ryoo, Hyun‐Mo , Dietz, Allan B. , Wijnen, André J. van , Camilleri, Emily , Kakar, Sanjeev , Westendorf, Jennifer J. , van Wijnen, Andre J , Dietz, Allan B , McGee-Lawrence, Meghan E , Camilleri, Emily

Mayo Clinic

Journal of Cellular Physiology | June 9, 2014 | Volume: 230 | Issue: 1 | Pages: 52-62

10.1002/jcp.24680 | PMID 24912092 Get It

Human adipose‐derived mesenchymal stromal cells (AMSCs) grown in platelet lysate are promising agents for therapeutic tissue regeneration. Here, we investigated whether manipulation of epigenetic events by the clinically relevant histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) alters differentiation of AMSCs. The multipotency of AMSCs was validated by their ability to differentiate into osteogenic, chondrogenic, and adipogenic lineages. High‐throughput RNA sequencing and RT‐qPCR established that human histone deacetylases (HDAC1 to HDAC11, and SIRT1 to SIRT7) are differentially expressed in AMSCs. SAHA induces hyper‐acetylation of histone H3 and H4, stimulates protein expression of the HDAC‐responsive gene SLC9A3R1/NHERF1 and modulates the AKT/FOXO1 pathway. Biologically, SAHA interferes with osteogenic, chondrogenic and adipogenic lineage commitment of multipotent AMSCs. Mechanistically, SAHA‐induced loss of differentiation potential of uncommitted AMSCs correlates with multiple changes in the expression of principal transcription factors that control mesenchymal or pluripotent states. We propose that SAHA destabilizes the multi‐potent epigenetic state of uncommitted human AMSCs by hyper‐acetylation and perturbation of key transcription factor pathways. Furthermore, AMSCs grown in platelet lysate may provide a useful biological model for screening of new HDAC inhibitors that control the biological fate of human mesenchymal stromal cells. J. Cell. Physiol. 230: 52–62, 2015. © 2014 Wiley Periodicals, Inc.
High‐Resolution Molecular Validation of Self‐Renewal and Spontaneous Differentiation in Clinical‐Grade Adipose‐Tissue Derived Human Mesenchymal Stem Cells
Dudakovic, Amel , Camilleri, Emily T. , Riester, Scott M. , Lewallen, Eric A. , Kvasha, Sergiy M., Chen, Xiaoyue , Radel, Darcie J., Anderson, Jarett M., Nair, Asha, Evans, Jared M., Krych, Aaron J. , Smith, Jay , Deyle, David R. , Stein, Janet L. , Im, Hee‐Jeong , Cool, Simon M. , Dietz, Allan B. , Wijnen, André J. van , Camilleri, Emily , Stein, Gary S. , Westendorf, Jennifer J. , Kakar, Sanjeev , van Wijnen, Andre J , Krych, Aaron J , Dietz, Allan B , Camilleri, Emily

Mayo Clinic

Journal of Cellular Biochemistry | June 6, 2014 | Volume: 115 | Issue: 10 | Pages: 1816-1828

10.1002/jcb.24852 | PMID 24905804 Get It

AbstractImproving the effectiveness of adipose‐tissue derived human mesenchymal stromal/stem cells (AMSCs) for skeletal therapies requires a detailed characterization of mechanisms supporting cell proliferation and multi‐potency. We investigated the molecular phenotype of AMSCs that were either actively proliferating in platelet lysate or in a basal non‐proliferative state. Flow cytometry combined with high‐throughput RNA sequencing (RNASeq) and RT‐qPCR analyses validate that AMSCs express classic mesenchymal cell surface markers (e.g., CD44, CD73/NT5E, CD90/THY1, and CD105/ENG). Expression of CD90 is selectively elevated at confluence. Self‐renewing AMSCs express a standard cell cycle program that successively mediates DNA replication, chromatin packaging, cyto‐architectural enlargement, and mitotic division. Confluent AMSCs preferentially express genes involved in extracellular matrix (ECM) formation and cellular communication. For example, cell cycle‐related biomarkers (e.g., cyclins E2 and B2, transcription factor E2F1) and histone‐related genes (e.g., H4, HINFP, NPAT) are elevated in proliferating AMSCs, while ECM genes are strongly upregulated (>10‐fold) in quiescent AMSCs. AMSCs also express pluripotency genes (e.g., POU5F1, NANOG, KLF4) and early mesenchymal markers (e.g., NES, ACTA2) consistent with their multipotent phenotype. Strikingly, AMSCs modulate expression of WNT signaling components and switch production of WNT ligands (from WNT5A/WNT5B/WNT7B to WNT2/WNT2B), while upregulating WNT‐related genes (WISP2, SFRP2, and SFRP4). Furthermore, post‐proliferative AMSCs spontaneously express fibroblastic, osteogenic, chondrogenic, and adipogenic biomarkers when maintained in confluent cultures. Our findings validate the biological properties of self‐renewing and multi‐potent AMSCs by providing high‐resolution quality control data that support their clinical versatility. J. Cell. Biochem. 115: 1816–1828, 2014. © 2014 Wiley Periodicals, Inc.
Radiosurgery is an Effective Treatment for Recurrent Esthesioneuroblastoma: A Multicenter Study
Link, Michael J. , Sheehan, Jason P. , Xu, Zhiyuan , Mathieu, David , Kano, Hideyuki , Lunsford, L. Dade , Van Gompel, Jamie J, Gompel, Jamie J. Van , Mathieu, David

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | June 4, 2014 | Volume: 75 | Issue: 06 | Pages: 409-414

10.1055/s-0034-1378151 | PMID 25452899 Get It

microRNA‐Mediated Survivin Control of Pluripotency
Kapinas, Kristina, Kim, Heesun , Mandeville, Matthew, Martin‐Buley, Lori A., Lian, Jane B. , Wijnen, André J. van , Stein, Janet L. , Croce, Carlo Maria , Altieri, Dario C. , Stein, Gary S. , van Wijnen, Andre J

Mayo Clinic

Journal of Cellular Physiology | June 2, 2014 | Volume: 230 | Issue: 1 | Pages: 63-70

10.1002/jcp.24681 | PMID 24891298 Get It

Understanding the mechanisms that sustain pluripotency in human embryonic stem cells (hESCs) is an active area of research that may prove useful in regenerative medicine and will provide fundamental information relevant to development and cancer. hESCs and cancer cells share the unique ability to proliferate indefinitely and rapidly. Because the protein survivin is uniquely overexpressed in virtually all human cancers and in hESCs, we sought to investigate its role in supporting the distinctive capabilities of these cell types. Results presented here suggest that survivin contributes to the maintenance of pluripotency and that post‐transcriptional control of survivin isoform expression is selectively regulated by microRNAs. miR‐203 has been extensively studied in human tumors, but has not been characterized in hESCs. We show that miR‐203 expression and activity is consistent with the expression and subcellular localization of survivin isoforms that in turn modulate expression of the Oct4 and Nanog transcription factors to sustain pluripotency. This study contributes to understanding of the complex regulatory mechanisms that govern whether hESCs proliferate or commit to lineages. J. Cell. Physiol. 230: 63–70, 2015. © 2014 Wiley Periodicals, Inc.